Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase, Aminoimidazole carboxamide formyltransferase (TS, DHFR, GART, AICAR Tfase)

The query provided a list of four distinct enzymes—Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase, and Aminoimidazole carboxamide formyltransferase—and incorrectly grouped them as a single target. While they are centrally involved in nucleotide metabolism (folate and purine pathways) and are recognized therapeutic targets, especially in oncology, they are four separate molecular entities. Each enzyme has individual therapeutic relevance and can be targeted distinctly. They are sometimes encoded together as bifunctional/trifunctional proteins in lower organisms but are usually distinct in humans. As a group, they represent critical enzymes for DNA and purine biosynthesis, making them classic targets in cancer treatment through antimetabolite and antifolate drugs.

Other names

TSTYMSDHFRGARTGAR TfasePhosphoribosylglycinamide formyltransferaseGRTAICAR transformylaseATICBifunctional purine biosynthesis protein PURH

Targeting these enzymes, often with antimetabolites or antifolates, primarily involves inhibition of enzyme activity to disrupt nucleotide biosynthesis (DNA, RNA, purines) through mechanisms such as covalent inhibition, competitive inhibition with natural substrates, or pseudo-irreversible binding, leading to cell growth arrest and death.